Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YR-G346
- Development stage
- Preclinical
- Lead developer
- Sichuan Enray Pharmaceutical Sciences
- Modality
- Small Molecules
01
Overview
YR-G346 is a preclinical small molecule glutathione peroxidase 4 (GPX4) inhibitor being developed by Sichuan Enray Pharmaceutical Sciences. It is designed to target the active site of selenocysteine in the GPX4 protein, thereby blocking the glutathione regeneration pathway and promoting ferroptosis (iron-dependent cell death) in tumor cells. Preclinical studies have demonstrated that YR-G346 possesses superior metabolic stability and tumor penetration compared to competing candidates in its class. The program is currently in preclinical development, with IND-enabling studies planned by 2028 for the treatment of oncology indications.
02
Targets
GPX4 (Glutathione peroxidase 4)
Beyond the preview
Go deeper on YR-G346.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YR-G346.